PKC inhibition overcomes chemo-resistance in TNBC by restoring Aurora kinase B expression

Triple negative breast cancer (TNBC) poses a significant challenge due to its high mortality rates, primarily attributed to resistance against chemotherapy regimens containing taxanes like paclitaxel. Overcoming this resistance is imperative for improving patient outcomes. In this context, the study aimed to identify more efficient combinatorial strategies to tackle with paclitaxel resistance in TNBC. Overall design: Chemo-resistant TNBC cells (termed SUM159-R) were treated with paclitaxel(500nM)/enzastaurin(2.5uM) alone or in combination. 24h later, cell pellets were collected and subjected to RNA extraction,followed by sequencing.